期刊文献+

造血干细胞移植在原发性骨髓纤维化治疗中的应用 被引量:3

Application of hematopoietic stem cell transplantation in the treatment of primary myelofibrosis
原文传递
导出
摘要 药物及对症支持治疗仍然是原发性骨髓纤维化(PMF)的主要治疗方法,但是其仅能改善患者症状而无法改变PMF的自然病程,而造血干细胞移植是目前治愈PMF唯一有效的手段.然而,严重的移植相关并发症限制了其在PMF患者中的广泛开展.文章就PMF患者造血干细胞移植过程中供者的选择、预处理方式、影响移植成功的因素等作一综述. Drugs and symptomatic and supportive treatment are still the main treatment in the primary myelofibrosis (PMF),but they can only improve symptoms without the natural course change of PMF.Hematopoietic stem cell transplantation (HSCT) is the only curable means to PMF,however,serious transplantrelated complications limit its extensive application in PMF patients.In this paper,donor selection process,pretreatment,successful transplantation factors and other factors on HSCT in PMF patients will be reviewed.
出处 《白血病.淋巴瘤》 CAS 2016年第5期314-317,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金,江苏省重点研发计划(BL2012022) National Natural Science Foundation of China,Key Plan of Research and Development of Jiangsu Province
关键词 原发性骨髓纤维化 造血干细胞移植 Primary myelofibrosis Hematopoietic stem cell transplantation
  • 相关文献

参考文献18

  • 1McLornan DP, Mead AJ, Jackson G, et al. Allogeneic stem cell transplantation for myelofibrosis in 2012 [ J ]. Br J Haemato|, 2012, 157 ( 4 ) : 413-425. DOh 10.1111/j.1365-2141.2012.09107.
  • 2Bhagwat N, Levine RL, Koppikar P, et al. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms [J]. lnt J Hematol, 2013,97 ( 6 ) :695-702.
  • 3Abelsson J, Merup M, Birgeg~d G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries [ J ]. Bone Marrow Transplant, 2012, 47 (3) : 380-386.
  • 4黄达永,王昭.骨髓增殖性肿瘤治疗与发病机制的研究进展[J].白血病.淋巴瘤,2015,24(7):408-411. 被引量:4
  • 5Gupta V, Foltz L, Sirhan S, et al. Emerging therapeutic options for myelofibrosis: a Canadian perspective [ J ]. Am J Blood Res, 2012, 2(3 ) : 170-186.
  • 6Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis [ J ]. Br J Haematol, 2012, 158 ( 4 ) : 453-471. DOI: 10.1111/j.1365-2141.2012.09179.
  • 7Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia [ J ]. Biol Blood Marrow Transplant, 2007, 13 ( 3 ) : 355-365.
  • 8Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis [ J ]. Biol Blood Marrow Transplant, 2010, 16( 3 ) : 358-367. DOI: 10.1016/j.bbmt.2009.10.025.
  • 9Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietie stem cell transplantation in myelofibrosis the 20-year experience of the Gruppo haliano Trapianto di Midollo Osseo ( GITMO ) [ J ]. Haematologica, 2008, 93 ( 10 ) : 1514-1522. DOh 10.3324/haematol. 12828.
  • 10Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research [ J ]. Biol Blood Marrow Transplant, 2014, 20 ( 1 ) : 89-97. DOI: 10.1016/j.bbmt.2013.10.018.

二级参考文献15

  • 1Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [ J ]. Cancer Cell, 2005, 7 ( 4 ) : 387-397.
  • 2Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [ J ]. N Engl J Med, 2007, 356 ( 5 ) : 459-468.
  • 3Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of ealretieulin in myeloproliferative neoplasms [ J]. N Engl J Med, 2013, 369 ( 25 ) : 2379-2390.
  • 4Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1 182 patients [ J ]. Blood, 2006, 108 ( 10 ) : 3472-3476.
  • 5Bandi SR, Brandts C, Rensinghoff M, et al. E3 ligase-defeetive Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease[ J 1. Blood, 2009, 114( 19 ) : 4197-4208.
  • 6Koren-Miehowitz M, Gery S, Tabayashi T, et al. SH2B3 ( LNK ) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F [ J ]. Br J Haematol, 2013, 161 ( 6 ) : 811-820.
  • 7Haan S, Wuller S, Kaezor J, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine- independent signaling [ J ]. Oneogene, 2009, 28 ( 34 ) : 3069-3080.
  • 8Brecqueville M, Rey J, Bertueci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms [ J ]. Genes Chromosomes Cancer, 2012, 51 ( 8 ) : 743-755.
  • 9Viny AD, Levine RL. Genetics of myeloproliferative neoplasms [ J ]. Cancer J, 2014, 20( 1 ) : 61-65.
  • 10Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression [ J ]. Blood, 2011, 118 ( 1 ) : 167-176.

共引文献3

同被引文献18

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部